Study #2020-1029
A Phase 1B Trial of Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (= 65) Patients with Primary CNS Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab
Description
The primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms of a tolerated dose (based on dose-limiting toxicities) for the expansion phase of the study (Stage 2).The primary objective of Stage 2 is to evaluate the efficacy of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in terms of the 2-year progression-free survival rate and compare to relevant historical controls
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Brain and Nervous System, Eye and Orbit
Study phase:
Phase I
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-466-0416
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.